Literature DB >> 23136614

Hybrid capture II for high-risk human papillomavirus DNA testing to detect cervical precancerous lesions: A qualitative and quantitative study.

Li Ma1, Mei-Lu Bian, Jiao-Ying Cheng, Wei Xiao, Min Hao, Juan Zhu, Ying Chen, Jun Liu.   

Abstract

Hybrid capture II (HC-II) is the only technique that can be used in clinical human papillomavirus (HPV) DNA detection. However, there is controversy in regards to how to analyze and assess the viral load of high-risk (HR)-HPV by use of HC-II and the relation between viral load and cervical lesions. In this study, we analyzed the results of a sequential screening of outpatients at the Department of Obstetrics and Gynecology of the China-Japan Friendship Hospital, and we aimed to explore the relationship between HR-HPV viral load and the severity of cervical lesions, and to clarify the clinical significance of the titer of HR-HPV DNA determined by HC-II. Using HC-II, 2,761 women were screened for HR-HPV DNA combined with cytological testing using liquid-based cytology. All women with HR-HPV-positive results or abnormalities in cytology underwent a cervical biopsy through colposcopy. Cervical biopsies were taken in 1,051 women. The HR-HPV infection rate was 78.35% (76/97) in HPV-associated lesions, 87.33% (193/221) in cervical intraepithelial neoplasia (CIN) I, 94.74% (144/152) in CIN II, 100% (178/178) in CIN III and 100% (20/20) in invasive cervical cancer (ICC), respectively (P<0.05). Based on the criteria of histopathology, the sensitivity of HR-HPV DNA testing by HC-II for detecting high-grade cervical lesions was 97.71%, the specificity was 79.64%, the positive-predictive value was 41.06% and the negative-predictive value was 99.59%. The viral loads of HR-HPV DNA were 512.15±764.19 in HPV-associated lesions, 753.95±978.27 in CIN I, 871.08±1003.52 in CIN II, 603.40±740.25 in CIN III and 466.44±673.05 in ICC, respectively. In conclusion, the positive rate of HR-HPV increased significantly in accordance with the severity of cervical lesions. The viral loads of cervical inflammatory lesions were markedly lower than CINs and ICC. The viral loads of HR-HPV DNA tested by HC-II had no correlation with the grade of cervical lesions.

Entities:  

Year:  2010        PMID: 23136614      PMCID: PMC3490331          DOI: 10.3892/etm_00000031

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  13 in total

1.  Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test?

Authors:  Jaume Ordi; Imma Alonso; Aureli Torné; Roser Esteve; Erika Sierra; Elias Campo; Luis M Puig-Tintoré
Journal:  Gynecol Oncol       Date:  2005-08-19       Impact factor: 5.482

2.  Human papillomavirus testing and conventional pap smear cytology as optional screening tools of women at different risks for cervical cancer in the countries of the former soviet union.

Authors:  Stina Syrjänen; Irena P Shabalova; Nicolaj Petrovichev; Vladimir P Kozachenko; Tatjana Zakharova; Julia Pajanidi; Jurij I Podistov; Galina Chemeris; Larisa G Sozaeva; Elena V Lipova; Irena Tsidaeva; Olga G Ivanchenko; Alla A Pshepurko; Sergej Zakharenko; Raisa Nerovjna; Ludmila B Kljukina; Oksana A Erokhina; Marina F Branovskaja; Maritta Nikitina; Valerija Grunberga; Alexandr Grunberg; Anna Juschenko; Piero Tosi; Marcella Cintorino; Rosa Santopietro; Kari J Syrjänen
Journal:  J Low Genit Tract Dis       Date:  2002-04       Impact factor: 1.925

3.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 4.  The 2001 Bethesda System terminology.

Authors:  Barbara S Apgar; Lauren Zoschnick; Thomas C Wright
Journal:  Am Fam Physician       Date:  2003-11-15       Impact factor: 3.292

5.  Management of women who test positive for high-risk types of human papillomavirus: the HART study.

Authors:  J Cuzick; A Szarewski; H Cubie; G Hulman; H Kitchener; D Luesley; E McGoogan; U Menon; G Terry; R Edwards; C Brooks; M Desai; C Gie; L Ho; I Jacobs; C Pickles; P Sasieni
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

6.  [Preliminary study on the relationship between loads of human papillomavirus in cervical carcinoma and cervical intraepithelial neoplasia].

Authors:  Shu-min Li; Wen-hua Zhang; Ling-ying Wu; Fang-hui Zhao; Man-ni Huang; Nan Li; Feng Chen
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  2004-06

7.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

8.  Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Authors:  Mark E Sherman; Attila T Lorincz; David R Scott; Sholom Wacholder; Philip E Castle; Andrew G Glass; Iwona Mielzynska-Lohnas; Brenda B Rush; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506

Review 9.  [Role of high-risk human papillomavirus testing in the screening and management of cervical cancer precursors].

Authors:  Ying Jin; Ling-ya Pan
Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao       Date:  2007-10

10.  Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions.

Authors:  C Clavel; J Cucherousset; M Lorenzato; S Caudroy; J M Nou; P Nazeyrollas; M Polette; J-P Bory; R Gabriel; C Quereux; P Birembaut
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

View more
  2 in total

1.  Human papillomavirus genotype prevalence in the women of Shanghai, China and its association with the severity of cervical neoplasia.

Authors:  Jingbo Wu; Xiaojing Li; Xiuping Liu; Zuhua Gao
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

2.  Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India.

Authors:  Kavita V Anand; Sharmila A Pimple; Atanu Bhattacharjee; Gauravi A Mishra; Surendra S Shastri
Journal:  Asian Pac J Cancer Prev       Date:  2021-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.